ATE448189T1 - Glycerin-peg-derivate als inhibitoren der cyclooxigenase-2 und der phospholipase-a2 - Google Patents

Glycerin-peg-derivate als inhibitoren der cyclooxigenase-2 und der phospholipase-a2

Info

Publication number
ATE448189T1
ATE448189T1 AT02756086T AT02756086T ATE448189T1 AT E448189 T1 ATE448189 T1 AT E448189T1 AT 02756086 T AT02756086 T AT 02756086T AT 02756086 T AT02756086 T AT 02756086T AT E448189 T1 ATE448189 T1 AT E448189T1
Authority
AT
Austria
Prior art keywords
phospholipase
group
cyclooxigenase
glycerin
inhibitors
Prior art date
Application number
AT02756086T
Other languages
English (en)
Inventor
Brian Keller
Original Assignee
Biozone Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26959001&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE448189(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biozone Lab Inc filed Critical Biozone Lab Inc
Application granted granted Critical
Publication of ATE448189T1 publication Critical patent/ATE448189T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32Polymers modified by chemical after-treatment
    • C08G65/329Polymers modified by chemical after-treatment with organic compounds
    • C08G65/331Polymers modified by chemical after-treatment with organic compounds containing oxygen
    • C08G65/332Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof
    • C08G65/3322Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof acyclic
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115Fatty acids or derivatives thereof; Fats or oils
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/22Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
    • C07C69/30Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with trihydroxylic compounds
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/902Specified use of nanostructure
    • Y10S977/904Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/926Topical chemical, e.g. cosmetic or sunscreen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Detergent Compositions (AREA)
AT02756086T 2001-03-23 2002-03-22 Glycerin-peg-derivate als inhibitoren der cyclooxigenase-2 und der phospholipase-a2 ATE448189T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27825701P 2001-03-23 2001-03-23
US09/877,334 US6495596B1 (en) 2001-03-23 2001-06-07 Compounds and methods for inhibition of phospholipase A2 and cyclooxygenase-2
PCT/US2002/011155 WO2002102757A1 (en) 2001-03-23 2002-03-22 Glycerol-peg-derivatives as inhibitors of cyclooxygenase-2 and phospholipase-a2

Publications (1)

Publication Number Publication Date
ATE448189T1 true ATE448189T1 (de) 2009-11-15

Family

ID=26959001

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02756086T ATE448189T1 (de) 2001-03-23 2002-03-22 Glycerin-peg-derivate als inhibitoren der cyclooxigenase-2 und der phospholipase-a2

Country Status (6)

Country Link
US (1) US6495596B1 (de)
EP (1) EP1381587B1 (de)
AT (1) ATE448189T1 (de)
CA (1) CA2447811C (de)
DE (1) DE60234329D1 (de)
WO (1) WO2002102757A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS4518A (is) * 1997-07-09 1999-01-10 Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group Nýtt lyfjaform fyrir bóluefni
US6998421B2 (en) * 2001-06-07 2006-02-14 Biozone Laboratories, Inc. Compounds and methods for inhibition of phospholipase A2 and cyclooxygenase - 2
WO2003039533A1 (en) * 2001-11-06 2003-05-15 The Brigham And Women's Hospital, Inc. Lipoxins and aspirin-triggered lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases
US20050106122A1 (en) * 2002-02-25 2005-05-19 Sveinbjorn Gizurarson Absorption enhancing agent
EA200401565A1 (ru) * 2002-05-24 2005-04-28 Неофарм, Инк. Способ получения кардиолипина или аналога кардиолипина (варианты), способ получения липосомы и композиция кардиолипина для лечения заболеваний (варианты)
CA2486967A1 (en) * 2002-05-24 2003-12-04 Neopharm, Inc. Cardiolipin compositions their methods of preparation and use
US6855332B2 (en) * 2002-07-03 2005-02-15 Lyfjathroun Hf. Absorption promoting agent
US20050277611A1 (en) * 2002-10-16 2005-12-15 Neopharm, Inc. Cationic cardiolipin analoges and its use thereof
BRPI0510004A (pt) * 2004-04-20 2007-09-18 Univ Chicago artigo de manufatura, métodos para administrar uma composição terapêutica a um epitélio de um indivìduo, para tratar uma condição mediada por micróbio de um epitélio de um indivìduo, para melhorar um sintoma de uma condição e para prevenir uma condição, e, uso de composto tipo peg pma
US20050244367A1 (en) * 2004-05-03 2005-11-03 Ilypsa, Inc. Phospholipase inhibitors localized in the gastrointestinal lumen
US7282224B1 (en) 2006-06-09 2007-10-16 Guthy-Renker Corporation Pain relief composition
US20080107747A1 (en) * 2006-10-23 2008-05-08 Roederer Joy E Pain relief composition
JP5523114B2 (ja) * 2007-03-08 2014-06-18 モコ セラピューティクス エルエルシー 傷跡が残ることを防止する及び減少させる被覆製剤
US20110171288A1 (en) * 2008-02-20 2011-07-14 Fatemeh Mohammadi Topical compositions and methods for whitening skin
AU2010271205A1 (en) * 2009-07-09 2012-02-09 Moko Therapeutics Llc. Method of wound healing and scar modulation
CN106290351A (zh) * 2015-06-03 2017-01-04 舒泰神(北京)生物制药股份有限公司 一种磷脂酶a2的活性测定方法
US10702475B2 (en) 2017-09-05 2020-07-07 Richard Rigg Liposome containing compositions and their use in personal care and food products
JP6805385B1 (ja) * 2020-08-31 2020-12-23 ジェイ−ネットワーク,インコーポレイテッド 表皮内の保湿関連物質の発現増強剤
JP6860739B1 (ja) * 2020-11-20 2021-04-21 ジェイ−ネットワーク,インコーポレイテッド 表皮内の抗酸化物質の発現増強剤

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5001234A (en) 1987-04-16 1991-03-19 The Upjohn Company Cyclic hydrocarbons with an aminoalkyl sidechain
US5659049A (en) 1988-02-18 1997-08-19 Virginia Commonwealth University Antioxidant, antiphospholipase derivatives of ricinoleic acid
US5122536A (en) 1989-10-12 1992-06-16 Perricone Nicholas V Method for the topical treatment of psoriasis
JPH04134077A (ja) 1990-09-21 1992-05-07 Taiho Yakuhin Kogyo Kk イソオキサゾール化合物
EP0543417A1 (de) 1991-11-22 1993-05-26 Lipogenics, Incorporated Tocotrienole und Focotrienol-ähnliche Verbindungen und Verfahren zu ihrer Verwendung
US5451686A (en) 1994-04-15 1995-09-19 Allergan, Inc. 3 and 5 alkyl and phenyl 4-(hydroxy or acyloxy)-alkyl substituted 2(5H)-furanones as anti-inflammatory agents
FR2750426B1 (fr) 1996-06-28 1998-08-07 Cird Galderma Nouveaux composes biaryles heterocycliques et leur utilisation en medecine humaine ou veterinaire ainsi qu'en cosmetique
US5863560A (en) 1996-09-11 1999-01-26 Virotex Corporation Compositions and methods for topical application of therapeutic agents
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
DE19909552C1 (de) * 1999-03-04 2000-07-27 Goldwell Gmbh Haarwaschmittel

Also Published As

Publication number Publication date
EP1381587B1 (de) 2009-11-11
CA2447811C (en) 2011-11-29
US6495596B1 (en) 2002-12-17
CA2447811A1 (en) 2002-12-27
WO2002102757A1 (en) 2002-12-27
EP1381587A1 (de) 2004-01-21
US20020198260A1 (en) 2002-12-26
DE60234329D1 (de) 2009-12-24

Similar Documents

Publication Publication Date Title
ATE448189T1 (de) Glycerin-peg-derivate als inhibitoren der cyclooxigenase-2 und der phospholipase-a2
DK1206474T3 (da) Sulfonylphenylpyrazolforbindelser anvendelige som cox-2-inhibitorer
DE60027135D1 (de) Inhibitoren für wachstumdifferenzierungsfaktor und ihre anwendungen
MA31167B1 (fr) Inhibiteurs de l'activite de akt
DK1754707T3 (da) Multicykliske forbindelser og anvendelse deraf som inhibitorer af PARP-, VEGFR2- og MLK3-enzymer
MXPA05010711A (es) Compuestos y composiciones novedosos como inhibidores de proteina-quinasa.
BRPI0513916A (pt) moduladores de pirrol-piridina cinase
MY142589A (en) Benzimidazole derivatives : preparation and pharmaceutical applications
BRPI0518228B8 (pt) inibidores de cinesina mitótica e uso dos mesmos
BRPI0514395A (pt) uso terapêutico de inibidores de rtp801
DK1590340T3 (da) Histondeacetylase-inhibitorer
ECSP10010735A (es) Compuestos químicos 251
ATE489360T1 (de) Inhibitoren der histon-deacetylase
NO20014986L (no) 4,5-diaryl-3(2H)-furanonderivater som cyklooksygenase-2- inhibitorer
MX2008010462A (es) Inhibidores de histona desacetilasa.
DE60319158D1 (de) Pyrazoloisoquinolinenderivaten als kinase inhibitoren
EA201100604A1 (ru) Соединения пиридиловых ингибиторов передачи сигналов белком hedgehog, способ их получения, композиция и способы лечения рака и ингибирований ангиогенеза и сигнального пути hedgehog в клетках на их основе
DK0971713T3 (da) Anvendelse af cholinesteraseinhibitorer til behandling af opmærksomhedsforstyrrelser
UY27362A1 (es) Métodos de usar inhibidores de epóxido hidrolasa soluble
BRPI0514549A (pt) ácidos de pirrol-naftila como inibidores de pai-1
BRPI0507626A (pt) compostos e composiçoes como moduladores de lxr
UY30918A1 (es) Moduladores de lta4h y sus usos
ATE452884T1 (de) Arylmethylamin-derivate zur verwendung als inhibitoren von tryptase
BR0314223A (pt) Compostos fenil-indol para modular ige e inibir proliferação celular
ATE414526T1 (de) Zubereitungen zur behandlung von arthritischen erscheinungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties